庆大霉素单药不足以清除咽部淋球菌
这项单臂非盲临床试验在2018年9月至2019年3月入组咽部淋球菌感染的男男性行为者,给予单剂360 mg庆大霉素肌注后4-7天培养复查。13例入组、10例可评估者中仅2例(20% [95% CI, 2.5%-55.6%])治愈,研究因疗效差提前终止,提示庆大霉素单药无法清除咽部淋球菌。
要点
- 庆大霉素单药360 mg肌注治疗咽部淋球菌的治愈率仅20%(95% CI, 2.5%-55.6%)。
- 研究因疗效差提前终止,疗效与庆大霉素峰浓度或MIC无关。
- CDC替代方案(庆大霉素240 mg+阿奇霉素2 g)应谨慎使用,因阿奇霉素耐药上升且庆大霉素咽部疗效差。
核心结论
- 庆大霉素单药无法从咽部清除淋球菌,治愈率低。
研究设计与样本
- 单臂、非盲临床试验,2018年9月至2019年3月入组核酸扩增试验诊断咽部淋球菌感染的男男性行为者。
- 受试者接受单剂360 mg庆大霉素肌注,4-7天后培养复查,计划入组50例可评估者,并在n=10和n=25时进行中期分析。
主要发现
- 13例入组,10例可评估,仅2例治愈(20% [95% CI, 2.5%-55.6%])。
- 疗效与庆大霉素峰浓度(Cmax)或最小抑菌浓度(MIC)无关。
- 无受试者发生肾功能不全,平均肌酐变化百分比为+5.2%(范围,-6.7%至21.3%)。
- 6例(46%)出现头痛,均判定与治疗无关。
关键数值与推荐
- CDC指南推荐对头孢菌素过敏的淋病患者使用庆大霉素240 mg联合阿奇霉素2 g。
- 本研究采用庆大霉素单剂360 mg肌注,计划假设80%疗效时95% CI为66%-90%。
临床怎么用
- 临床医生不应使用庆大霉素单药治疗咽部淋球菌感染。
- 使用CDC当前替代方案(庆大霉素240 mg+阿奇霉素2 g)时应谨慎,因阿奇霉素耐药上升且庆大霉素咽部疗效差。
局限性
- 研究为单臂非盲设计,样本量小(10例可评估),因疗效差提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Centers for Disease Control and Prevention (CDC) guidelines recommend 240 mg gentamicin plus 2 g azithromycin for the treatment of gonorrhea in cephalosporin-allergic patients. The efficacy of gentamicin alone in the treatment of pharyngeal gonorrhea is uncertain. METHODS: Between September 2018 and March 2019, we enrolled men who have sex with men with nucleic acid amplification test-diagnosed pharyngeal gonorrhea in a single-arm, unblinded clinical trial. Men received a single 360-mg intramuscular dose of gentamicin and underwent test of cure by culture 4-7 days later. The study measured creatinine at enrollment and test of cure, serum gentamicin concentration postdose to establish peak concentration (Cmax), and standard antimicrobial minimum inhibitory concentrations (MICs) by agar dilution. The trial was designed to establish a point estimate for gentamicin's efficacy for pharyngeal gonorrhea. We planned to enroll 50 evaluable participants; assuming gentamicin was 80% efficacious, the trial would establish a 95% confidence interval (CI) of 66%-90%. We planned interim analyses at n = 10 and n = 25. RESULTS: The study was stopped early due to poor efficacy. Of 13 enrolled men, 10 were evaluable, and only 2 (20% [95% CI, 2.5%-55.6%]) were cured. Efficacy was not associated with gentamicin Cmax or MIC. No participants experienced renal insufficiency. The mean creatinine percentage change was +5.2% (range, -6.7% to 21.3%). Six (46%) participants experienced headache, all deemed unrelated to treatment. CONCLUSIONS: Gentamicin alone failed to eradicate Neisseria gonorrhoeae from the pharynx. Clinicians should use caution when treating gonorrhea with the CDC's current alternative regimen (gentamicin 240 mg plus azithromycin 2 g) given increases in azithromycin resistance and gentamicin's poor efficacy at the pharynx. CLINICAL TRIALS REGISTRATION: NCT03632109.
引用
- Barbee LA, Soge OO, Morgan J, et al. Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx. Clin Infect Dis. 2020. PMID: 31712813. doi:10.1093/cid/ciz1109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。